Citation Impact
Citing Papers
Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates
2010
Factors Associated with the Development of Cross-Reactive Neutralizing Antibodies during Human Immunodeficiency Virus Type 1 Infection
2008
Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions
2014 Science
Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice
2023 StandoutNobel
Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques
2019 StandoutNobel
Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge
2017 StandoutNobel
Native‐like Env trimers as a platform for HIV ‐1 vaccine design
2017
Messenger RNA-Based Vaccines Against Infectious Diseases
2020 StandoutNobel
Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine
2017
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
The role of liposomes in clinical nanomedicine development. What now? Now what?
2019 Standout
mRNA-based therapeutics — developing a new class of drugs
2014 StandoutNobel
Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses
2010 StandoutNobel
Novel Approaches to Vaginal Delivery and Safety of Microbicides: Biopharmaceuticals, Nanoparticles, and Vaccines
2010
Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope
2009
PLGA-based nanoparticles: An overview of biomedical applications
2012 Standout
MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile
2003
Vaccination with Messenger RNA: A Promising Alternative to DNA Vaccination
2020 StandoutNobel
Elicitation of strong immune responses by a DNA vaccine expressing a secreted form of hepatitis C virus envelope protein E2 in murine and porcine animal models
2006
Biomedical applications of biodegradable polymers
2011 Standout
Recent advances in mRNA vaccine technology
2020 StandoutNobel
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
2021 StandoutNobel
Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes
2015 StandoutNobel
Delivery technologies for cancer immunotherapy
2019 Standout
Prospects for a vaccine against the hepatitis C virus
2005 StandoutNatureNobel
Recent advances with liposomes as pharmaceutical carriers
2005 Standout
Exploiting dendritic cells to improve vaccine efficacy
2002 StandoutNobel
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
2004 Standout
A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T‐cell immunity in vivo
2011 StandoutNobel
Glycotherapy: New Advances Inspire a Reemergence of Glycans in Medicine
2013 StandoutNobel
mRNA transcript therapy
2014 StandoutNobel
Increased surface expression of HIV-1 envelope is associated with improved antibody response in vaccinia prime/protein boost immunization
2017 StandoutNobel
Survey of the year 2003 commercial optical biosensor literature
2004
Nucleoside Modified mRNA Vaccines for Infectious Diseases
2016 StandoutNobel
Computational Design of Epitope-Scaffolds Allows Induction of Antibodies Specific for a Poorly Immunogenic HIV Vaccine Epitope
2010 StandoutNobel
Is developing an HIV-1 vaccine possible?
2010
Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins
2014
Role of adjuvants in modeling the immune response
2010
The ABC of clinical and experimental adjuvants—A brief overview
2009
Measuring the Adjuvant Activity of RNA Vaccines
2016 StandoutNobel
Recombinant HIV Envelope Proteins Fail to Engage Germline Versions of Anti-CD4bs bNAbs
2013
The way forward in HCV treatment — finding the right path
2007 StandoutNobel
Virus-like particles: Designing an effective AIDS vaccine
2006
SARS-CoV-2 vaccines in development
2020 StandoutNature
Vaccines for the prevention of HIV-1 disease
2001
Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures
2013 Standout
Exploiting dendritic cells to improve vaccine efficacy
2002 StandoutNobel
Induction of Broad CD4+and CD8+T-Cell Responses and Cross- Neutralizing Antibodies against Hepatitis C Virus by Vaccination with Th1-Adjuvanted Polypeptides Followed by Defective Alphaviral Particles Expressing Envelope Glycoproteins gpE1 and gpE2 and Nonstructural Proteins 3, 4, and 5
2008 StandoutNobel
Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates
2011 StandoutNobel
Exploiting dendritic cells to improve vaccine efficacy
2002 StandoutNobel
Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors
2013 StandoutScienceNobel
Enhanced Delivery and Potency of Self-Amplifying mRNA Vaccines by Electroporation in Situ
2013
Immunization of woodchucks with adjuvanted sHDAg (p24): immune response and outcome following challenge
2003 StandoutNobel
Antibody responses to human rotavirus (HRV) in gnotobiotic pigs following a new prime/boost vaccine strategy using oral attenuated HRV priming and intranasal VP2/6 rotavirus-like particle (VLP) boosting with ISCOM
2004
Nonviral delivery of self-amplifying RNA vaccines
2012
Activation of Natural Killer T Cells by α-Galactosylceramide Rapidly Induces the Full Maturation of Dendritic Cells In Vivo and Thereby Acts as an Adjuvant for Combined CD4 and CD8 T Cell Immunity to a Coadministered Protein
2003 StandoutNobel
Vaccine innovations for emerging infectious diseases—a symposium report
2019 StandoutNobel
Neutralizing antibodies to HIV-1 induced by immunization
2013
Kinetic mechanism for HIV-1 neutralization by antibody 2G12 entails reversible glycan binding that slows cell entry
2012
Contributions of Amino Acid Side Chains to the Kinetics and Thermodynamics of the Bivalent Binding of Protein L to Ig κ Light Chain
2004 StandoutNobel
Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses
2006 StandoutNobel
Progress towards a hepatitis C virus vaccine
2013 StandoutNobel
Cationic microparticles are a potent delivery system for a HCV DNA vaccine
2004 StandoutNobel
DNA vaccines: an historical perspective and view to the future
2010
Working together: interactions between vaccine antigens and adjuvants
2013
Design and Characterization of Stabilized Derivatives of Human CD4D12 and CD4D1
2011 StandoutNobel
Nanoparticle Size and Surface Chemistry Determine Serum Protein Adsorption and Macrophage Uptake
2011 Standout
Emerging Nanotechnology Approaches for HIV/AIDS Treatment and Prevention
2010
Surface Plasmon Resonance Sensors for Detection of Chemical and Biological Species
2008 Standout
Progress with induction of HIV broadly neutralizing antibodies in the Duke Consortia for HIV/AIDS Vaccine Development
2023 StandoutNobel
Structural insights into key sites of vulnerability on HIV ‐1 Env and influenza HA
2012
A Native-Like SOSIP.664 Trimer Based on an HIV-1 Subtype B env Gene
2015
Delivery of Protein Antigens to the Immune System by Fusion-Active Virosomes: A Comparison with Liposomes and ISCOMs
2002
Characterization of Hepatitis C Virus Core-Specific Immune Responses Primed in Rhesus Macaques by a Nonclassical ISCOM Vaccine
2001 StandoutNobel
Works of Yide Sun being referenced
Trimeric HIV Env provides epitope occlusion mediated by hypervariable loops
2014
Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits
2009
Comparative evaluation of trimeric envelope glycoproteins derived from subtype C and B HIV-1 R5 isolates
2007
Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein
2012
Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines
2006
Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen
2004
Effect of the strength of adsorption of HIV 1 SF162dV2gp140 to aluminum‐containing adjuvants on the immune response
2011
Quaternary structures of HIV Env immunogen exhibit conformational vicissitudes and interface diminution elicited by ligand binding
2011
Evaluation of Envelope Vaccines Derived from the South African Subtype C Human Immunodeficiency Virus Type 1 TV1 Strain
2005
Comparison of Immunity Generated by Nucleic Acid-, MF59-, and ISCOM-Formulated Human Immunodeficiency Virus Type 1 Vaccines in Rhesus Macaques: Evidence for Viral Clearance
1999
Antibody-Mediated Protection against Mucosal Simian-Human Immunodeficiency Virus Challenge of Macaques Immunized with Alphavirus Replicon Particles and Boosted with Trimeric Envelope Glycoprotein in MF59 Adjuvant
2010
Comparative Immunogenicity of Subtype A Human Immunodeficiency Virus Type 1 Envelope Exhibiting Differential Exposure of Conserved Neutralization Epitopes
2009